BioCentury
ARTICLE | Finance

Intranasal option

Why Canaan is backing Dauntless' intranasal somatostatin analog

February 25, 2017 1:01 AM UTC

Canaan Partners sees a clear market opportunity for a non-invasive somatostatin analog, prompting the VC to lead a $25 million series A extension for Dauntless Pharmaceuticals Inc.

The financing, announced Feb. 16, brings the round's final close to $32 million. Existing investor Sofinnova Ventures also participated. ...

BCIQ Company Profiles

Dauntless Pharmaceuticals Inc.